Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Neuropharmacology. 2016 Nov 25;114:156–167. doi: 10.1016/j.neuropharm.2016.11.015

Figure 1.

Figure 1

The dual FAAH and MAGL inhibitor SA-57 ameliorates allodynia and inflammation in the carrageenan inflammatory pain model. SA-57 (A) reverses carrageenan-induced allodynia, and (B) partially reverses carrageenan-induced edema. Tests were conducted 2 hr after i.p. administration of SA-57 produces reversal from allodynia. Filled symbols indicate at least p < 0.05 vs. vehicle. Data reflect mean ± SEM, n=6 mice per group.